Research Compares Menopause Treatment Options

A long-term study suggests non-hormonal options for hot flashes can be as effective as low-dose oral estradiol.

Updated on Oct. 23, 2026 in Women’s Health

A glass medical vial of clear liquid on a white laboratory counter. — The Menopause Society has published findings from the MsFLASH network trials, offering new comparisons between hormonal and non-hormonal treatment options for menopause. AI Illustration. Upload story photo >

Live Poll

Should the federal government increase funding for women's health research?

The Menopause Society recently reviewed findings from the long-running MsFLASH clinical trials network. The project evaluated 9 different interventions for menopause symptoms across 5 clinical trials, providing new insights into treatment efficacy for women navigating midlife health transitions.

Why it matters

By pooling data from over 1,300 participants, researchers were able to answer complex questions about menopause management that individual studies could not address on their own. This work helps clarify which treatments may be effective for symptoms like hot flashes and sleep disturbances.

The MsFLASH network pooled data from 5 clinical trials and 8 ancillary studies involving over 1,300 participants. The researchers evaluated 9 different interventions for menopause symptoms, noting that SSRIs and SNRIs showed efficacy similar to 0.5 mg low-dose oral estradiol.

The players

The Menopause Society

A professional organization dedicated to advancing the health and quality of life of women during menopause and beyond.

MsFLASH

A research network funded by the National Institutes of Health that conducted clinical trials on menopause symptom management.

National Institutes of Health

The primary agency of the United States government responsible for biomedical and public health research.

The details

The MsFLASH network utilized standardized measures across its trials to evaluate hot flashes, mood, sleep, and sexual function. By aggregating data and collecting over 16,000 biological specimens, investigators were able to perform deep analyses, including a dedicated study on the biology of vaginal symptoms. These findings help clinicians compare hormonal and non-hormonal treatment approaches more effectively.

From 2008 to 2022, the National Institutes of Health funded the MsFLASH network.
On October 20-24, 2026, The Menopause Society held its annual meeting in San Diego.

Health Landscape

The MsFLASH clinical trials network established a rigorous framework for studying multi-faceted menopause symptoms through pooled data analysis. This approach advances the broader medical trend toward evidence-based, personalized management for women in the midlife transition.

Understanding that certain non-hormonal medications may be as effective as low-dose estrogen for hot flashes is a conversation worth having with your physician. If you are currently exploring symptom management, review these findings with your doctor to discuss which options align with your history.

The takeaway

The study demonstrates that pooling clinical data allows for more robust conclusions regarding treatment efficacy for menopause symptoms. If you are experiencing persistent symptoms, keep a symptom diary to share with your provider to better evaluate which treatment pathways might be most appropriate for you.